TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00709826
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine: per package insert.
Study: NCT00709826
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib - per package insert.
Study: NCT00709826
Drug: apricoxib
Normalized name: Apricoxib
DrugBank: Apricoxib (DB12378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apricoxib: 100mg tablets, given orally
Study: NCT03661684
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg po q day of Prednisone for 3 days
Study: NCT02368470
Drug: Gemifloxacin-based triple therapy
DrugBank: Gemifloxacin (DB01155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
Study: NCT02518555
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03601871
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .
Study: NCT03601871
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4
Study: NCT03601871
Drug: 5-HT3 antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3
Study: NCT03445702
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1000mg once
Study: NCT02918084
Drug: Anastrozole or Letrozole or Exemestane
Normalized name: Medicated Pad or Tape
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant chemotherapy → Anastrozole or Letrozole or Exemestane once a day for 5 years (sequential arm)
Study: NCT02918084
Drug: Anastrozole or Letrozole or Exemestane
Normalized name: Medicated Pad or Tape
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant chemotherapy + Anastrozole or Letrozole or Exemestane once a day for 5 years (concurrent arm)
Study: NCT01941589
Drug: corticosteroids only
Normalized name: abiraterone and corticosteroids
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV corticosteroids only
Study: NCT01479348
Drug: Tetrahydrouridine (oral)
Normalized name: (4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine
DrugBank: Tetrahydrouridine (DB12484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose of THU is 3000 mg, oral
Study: NCT00457405
Drug: dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dipyridamole 200mg twice daily
Study: NCT01841619
Drug: IVIg
Normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled subjects will receive IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as some patients with CLE. The drug will be administered at 500 mg/kg/day on consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine. After 3 months of treatment, IVIg will be discontinued and the subjects will be monitored for additional 6 months for a possible relapse. In the case of relapse, which is expected to occur in \<25% subjects, the subjects will be re-treated by the standard protocol.
Study: NCT00503971
Drug: Vorinostat plus Erlotinib
Normalized name: Vorinostat
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I:~Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily~Phase II:~Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily
Study: NCT01946477
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01946477
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01946477
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03246529
Drug: Placebo +G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
Study: NCT00660010
Drug: Lupron (leuprolide acetate)
Normalized name: leuprolide acetate Prefilled Syringe [Lupron]
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
Study: NCT03211013
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour
Study: NCT02024984
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.~Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle.
Study: NCT00827190
Drug: ILS-920
Normalized name: ILS-920
DrugBank: ILS-920 (DB15422)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03786081
Drug: Tisotumab Vedotin
Normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given into the vein (IV)
Study: NCT03786081
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given via IV
Study: NCT03786081
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given via IV
Study: NCT03786081
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given via IV
Study: NCT02705859
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab.
Study: NCT02705859
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab IV weekly (4mg/kg on Cycle 1 Day 1 followed by 2 mg/kg IV weekly from Day 8).
Study: NCT01286766
Drug: DCS (docetaxel with cisplatin with TS-1)
Normalized name: DCS
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. S-1: 70 mg/m2 #2 bid PO, D1-14~2. Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8~3. Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks.
Study: NCT01286766
Drug: DCF (docetaxel with cisplatin with 5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. 5-FU: 1,000 mg/m2 CI, D1-3~2. Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by~3. Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.~   * Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)~  * treatment is repeated until 4 cycles
Study: NCT00828464
Drug: clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
Study: NCT00838357
Drug: Generic = Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
Study: NCT01953952
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03041311
Drug: Trilaciclib
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilaciclib IV
Study: NCT03041311
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin IV
Study: NCT03041311
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide IV
Study: NCT03041311
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab IV
Study: NCT04398732
Drug: Enbrel
Normalized name: Enbrel
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT02073487
Drug: T-DM1
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: antibody-drug conjugate of trastuzumab and emtansine
Study: NCT02073487
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-Her2 monoclonal antibody
Study: NCT02073487
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dual tyrosine kinase inhibitor (HER2 and EGFR)
Study: NCT02073487
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.
Study: NCT02073487
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: chemotherapy - microtubule inhibitor
Study: NCT02073487
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-HER2 monoclonal antibody
Study: NCT02395991
Drug: gadoxetic acid
Normalized name: Gadoxetic acid
DrugBank: Gadoxetic acid (DB08884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration
Study: NCT03049449
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
Study: NCT05670509
Drug: administration of Nasal midazolam in home group as a rescue medication for seizure control.
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children from home group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
Study: NCT00472693
Drug: Bevacizumab, Abraxane
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
Study: NCT00237133
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of Letrozole 2.5 mg orally adminnistered once a day
Study: NCT02744976
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months
Study: NCT00386841
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10 mg p.o. per day
Study: NCT03093402
Drug: JBT-101
Normalized name: JBT-101
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Study: NCT03662022
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
Study: NCT01636492
Drug: bitopertin
Normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT04488237
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of Vitamin D in patients with acute leukemia treated with methotrexate
Study: NCT02886702
Drug: Tazarotene Cream 0.05%
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene Cream 0.05% to cover only the lesions with a thin film.
Study: NCT02297698
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
Study: NCT02033356
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03486392
Drug: JNJ-64565111 Dose Level 1
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.
Study: NCT03486392
Drug: JNJ-64565111 Dose Level 2
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.
Study: NCT03486392
Drug: JNJ-64565111 Dose Level 3
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.
Study: NCT03486392
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
Study: NCT03633279
Drug: Branched chain amino acid
Normalized name: Branched Chain Amino Acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).
Study: NCT01225341
Drug: onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
Study: NCT03691714
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two hour infusion
Study: NCT03691714
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two hour infusion for loading dose followed by weekly one hour infusion
Study: NCT00607841
Drug: Ispinesib
Normalized name: Ispinesib
DrugBank: Ispinesib (DB06188)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/m2 dose as a 1-hour intravenous infusion.
Study: NCT00607841
Drug: Ispinesib
Normalized name: Ispinesib
DrugBank: Ispinesib (DB06188)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/m2 dose as a 1-hour intravenous infusion.
Study: NCT00607841
Drug: Ispinesib
Normalized name: Ispinesib
DrugBank: Ispinesib (DB06188)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg/m2 dose as a 1-hour intravenous infusion.
Study: NCT04035876
Drug: Camrelizumab plus apatinib
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200mg q2w iv and apatinib 250mg qd po.
Study: NCT05670509
Drug: administration of Buccal midazolam in home group as a rescue medication for seizure control.
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children from home group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
Study: NCT00055640
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.
Study: NCT00055640
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.
Study: NCT00575861
Drug: zileuton
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zileuton (Zyflo) 600mg qid for 2hr and for 30 days
Study: NCT05670509
Drug: administration of intramuscular midazolam in homegroup as a rescue medication for seizure control.
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children from home group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
Study: NCT05024006
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two intravenous loading doses, then daily infusion for 10 days
Study: NCT05024006
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two oral loading doses, then orally twice daily for 10 days
Study: NCT05024006
Drug: Lopinavir / Ritonavir
Normalized name: lopinavir / ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally twice daily for 14 days
Study: NCT05024006
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily injection for 6 days
Study: NCT05024006
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally twice daily for 10 days
Study: NCT00559091
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
Study: NCT01316042
Drug: sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 pills per day for 12 months
Study: NCT01316042
Drug: Metformin, glucophage
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 212.5mg pills/day for 12 months
Study: NCT02899169
Drug: Realgar-Indigo naturalis formula
Normalized name: indigo
DrugBank: Indigo (DB16862)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02899169
Drug: all-trans retinoic acid
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02899169
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02899169
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01812642
Drug: JNJ-37822681
Normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.
Study: NCT00502840
Drug: rituximab [MabThera/Rituxan]
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1g iv on days 1 and 15